Goserelin acetate for ovarian function protection in early breast cancer

Phase 3, randomised, open-label trial of goserelin in primary ovarian insufficiency (POI) (2 arms), sponsored by AstraZeneca. Primary endpoints: Ovarian function regained, defined as E2 measurements returning to premenopausal levels (equal to or above 20 pg/ml) and FSH measurements returning to premenopausal levels (less than or equal to 40… at 3 months and Ovarian function regained, defined as menstrual bleeding observed in two consecutive menstrual cycles at 3 months. Status: withdrawn.